Physician profile
James M Foelsch
NPI 1447219589
$2,540.50
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $256 · 2021: $385 · 2022: $507 · 2023: $650 · 2024: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065 · Education: $31.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.87 |
| Education | $31.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $533.72 | 2020-2024 | Mavenclad |
| Abbvie INC. | $204.10 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $201.52 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $190.13 | 2019-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $147.20 | 2019-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $124.79 | 2023-2024 | Trintellix, Hyqvia |
| Celgene Corporation | $119.91 | 2022-2024 | Zeposia |
| Ucb, INC. | $110.93 | 2021-2024 | Rystiggo |
| Greenwich Biosciences, INC. | $103.92 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $103.13 | 2019-2023 | Ultomiris |
| Genentech USA, INC. | $77.00 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
| Eisai INC. | $72.03 | 2021-2024 | |
| Allergan, INC. | $69.71 | 2020 | |
| Alkermes, INC. | $57.27 | 2023-2024 | Lybalvi, Aristada |
| Akcea Therapeutics, INC. | $55.27 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amylyx Pharmaceuticals, INC. | $54.97 | 2023 | Relyvrio |
| Lundbeck LLC | $53.25 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.25 | 2022-2023 | |
| Axsome Therapeutics, INC. | $40.00 | 2023 | Auvelity |
| Acadia Pharmaceuticals INC | $39.10 | 2019-2024 | Daybue |
| Tanabe Pharma America, INC. | $30.00 | 2023 | |
| Acorda Therapeutics, INC | $27.85 | 2019 | |
| Argenx US, INC. | $27.00 | 2024 | Vyvgart Hytrulo |
| Genzyme Corporation | $25.12 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Foelsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.